Genetische Befunde zu Schizophrenie
Abstract
Zusammenfassung: Schizophrene Erkrankungen zeichnen sich durch eine sehr heterogene Symptomatik mit übergreifenden Funktionsstörungen verschiedenster kognitiver Bereiche aus. Die vielfältigen Phänotypen werden durch das Zusammenwirken von genetischer Prädisposition und Umwelteinflüssen erklärt. Pathophysiologische Modelle beinhalten die Dopamin-Überschuss- sowie Glutamat-Mangel-Hypothese, die Radikal-Hypothese und die Hypothese entwicklungsbedingter versus degenerativer Genese. Neben den neurobiologischen Erklärungsansätzen geben Kopplungsstudien mit nachfolgenden Feinkartierungen Hinweise auf potentiell an der Pathophysiologie beteiligte Gene. Den wichtigsten Kandidatengenen, wie Dysbindin (DTNBP1), Neuregulin1 (NRG1) oder DISC-1 (disrupted-in schizophrenia-1), werden Einfluss auf die Signalübertragung sowie der Ausbildung und dem Erhalt der Struktur von neuronalen Netzwerken zugeschrieben. Zu ihnen werden zahlreiche weitere Gene gezählt. Insgesamt ist bei der Pathogenese der Schizophrenie von einer multifaktoriellen Entstehung mit der Interaktion von verschiedenen genetischen und neurobiologischen sowie exogenen Komponenten auszugehen.
Summary: Schizophrenia is characterized by a great heterogeneity of symptoms and functional deficits, especially of cognition. Different phenotypes are thought to result from the interaction of genetic predisposition and environmental factors. Pathophysiological models range from the dopamine and glutamate hypotheses to the hypothesis of free radicals and the hypotheses of neurodevelopment as opposed to neurodegeneration. In addition to the neurobiological approaches, linkage studies and subsequent finemappings deliver evidence with regard to genes potentially involved in schizophrenia. The most important candidate genes, such as dysbindin (DTNBP1), neuregulin (NRG1) and DISC-1 (disrupted-in schizophrenia-1), are thought to influence neurotransmission, as well as the development and maintenance of the structure of neuronal networks. The list of potential candidates includes numerous other genes as well. In conclusion, multiple genetic, neurobiological, and exogenous factors are assumed to interact in the pathogenesis of schizophrenia.
Literatur
2004a). GAD1 (2q31.1) which encodes glutamic acid decarboxylase (GAD67) is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Molecular Psychiatry, 9, 1– 8
(2004b). Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biological Psychiatry. 55, 976– 980
(2002). Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molecular Psychiatry, 7, 405– 411
(2001). A study of cranial computer tomograms in very early and early onset schizophrenia. Journal of Neural Transmission, 108, 1335– 1344
(2003). Molecular genetics of schizophrenia: a critical review. Journal of Psychiatry and Neurosciences, 28, 415– 429
(2004). The serotonin-2A receptor gene locus does not contain common polymorphisms or epigenetic variation affecting expression in adult brain. Molecular Psychiatry, 9, 109– 114
(2002). Obstetric complications and schizophrenia: historical and meta-analytic review. American Journal of Psychiatry, 159, 1080– 1092
(2002). Association and linkage analyses of RGS polymorphisms in schizophrenia. Human Molecular Genetics, 11, 1323– 1360
(2002). Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences USA, 99, 13675– 13680
(2003). White matter changes in schizophrenia evidence for myelin-related dysfunction. Archives of General Psychiatry, 60, 443– 456
(2007). Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population. Schizophrenia Research, 90, 123– 129
(2002). State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Molecular Psychiatry, 7, 995– 1001
(2001). Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biological Psychiatry, 50, 98– 107
(2001). Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences USA, 98, 6917– 6922
(1999). The gene encoding praline dehydrogenase modulates sensorimotor gating in mice. National Genetics, 21, 434– 439
(2005). Dysbindin (DTNBP1, 6q22.3) is associated with childhood onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). Journal of Autism and Developmental Disorders, 35, 831– 838
(1991). Schizophrenia Genesis. The Origins of Madness. New York: Freeman
(1982). Schizophrenia: The epigenetic puzzle. Cambridge, UK: Cambridge University Press
(2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences U.S.A., 98, 4746– 4751
(1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 112, 593– 624
(2006). Neuregulin 1 and schizophrenia: genetics, gene expression and neurobiology. Biological Psychiatry, 60, 132– 140
(2003). Decreased levels of D-Serine in patients with schizophrenia. Archives of General Psychiatry, 60, 576– 772
(2006). Genetic counselling for psychiatric disorders. Medical Jounal of Australia,, 185, 507– 510
(2004). Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder and bipolar disorder. American Journal of Human Genetics, 75, 862– 872
(1998). The new epidemiology of schizophrenia. Psychiatric Clinics of North America, 21, 1– 25
(2001). Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proceedings of the National Academy of Sciences USA, 98, 4634– 4639
(2005). Finding schizophrenia genes. The Journal of Clinical Investigation, 115, 1440– 1448
(1997). Catechol-O-Methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatry and Genetics, 7, 97– 101
(2006). Genetics of chromosome 15q13-q14 in schizophrenia. Biological Psychiatry, 60, 115– 122
(2003). Genome-scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. American Journal of Human Genetics, 73, 34– 48
(2006). Association study of the G-protein signalling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. European Journal of Human Genetics, 14, 1130– 1135
(2002). Genetic variation at the 22q11 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proceedings of the National Academy of Sciences USA, 99, 3717– 3722
(2002). Nicotine and familial vulnerability to schizophrenia: a discordant twin study. Journal of Abnormal Psychology, 111, 687– 693
(2002). 22q11 DS: Genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. International Journal of Development and Neurosciences, 20, 407– 419
(2000). Brain Research and Brain Research Reviews, 31, 130– 137
(2006). Increased mRNA levels of mitochondrial complex I 75-kDa subunit in whole blood cells of early onset schizophrenic patients. European Journal of Child and Adolescent Psychiatry, 15, 504– 507
(2002). Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. Journal of Neural Transmission, 109, 219– 234
(2005). DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signalling. Science, 310, 1187– 1191
(2000). Disruption of two novel genes by a translocation cosegregating with schizophrenia. Human Molecular Genetics, 9, 1415– 1423
(2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron, 28, 53– 67
(2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Molecular Psychiatry, 6, 293– 301
(2003). Recent advances in the neurobiology of schizophrenia. Molecular Interventions, 3, 27– 39
(2003). Disrupted-in schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Molecular Psychiatry, 8, 685– 694
(2002). The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry, 2, 8–
(2006). Association of the NRG1 gene and schizophrenia: a meta-analysis. Molecular Psychiatry, 11, 539– 546
(2004). A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophrenia Research, 71, 405– 416
(2003). Parental schizophrenia spectrum disorders in childhood-onset and adult-onset schizophrenia. American Journal of Psychiatry, 160, 490– 495
(2006). An update of the genetics of schizophrenia. Current Opinion in Psychiatry, 19, 158– 164
(2004). Evidence of novel neuronal functions of dysbindin, a susceptibility gene of schizophrenia. Human Molecular Genetics, 13, 2699– 2708
(2005). Lack of evidence for elevated obstetric complications in childhood onset schizophrenia. Biologial Psychiatry, 58, 10– 15
(2004). The molecular genetics of schizophrenia: new findings promise new insights. Molecular Psychiatry, 9, 14– 27
(2003). Monozygotic twins exhibit numerous epigenetic differences: clues to twins disconcordance?. Schizophrenia Bulletin, 29, 169– 178
(2006). The genetics and biology of DISC1 - an emerging role in psychosis and cognition. Biological Psychiatry, 60, 123– 131
(2004). Immediate communication. Mitochondrial dysfunction in Schizophrenia: evidence for compromised brain meta-bolism and oxidative stress. Molecular Psychiatry, 9, 684– 697
(2005). Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Molecular Psychiatry, 10, 213– 219
(2005). The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 10, 434– 449
(2005). The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuropsychopharmacology and Biological Psychiatry, 29, 1021– 1028
(2004). 22q11 deletion syndrome in childhood onset schizophrenia: an update. Molecular Psychiatry, 9, 225– 226
(2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71, 877– 892
(2000). Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. American Journal of Human Genetics, 67, 1201– 1207
(2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics, 71, 337– 348
(2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigations, 113, 1353– 1363
(1994). Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. European Journal of Biochemistry, 223, 1049– 1059
(1997). Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophrenia Research, 28, 1– 38
(2000). Schizophrenia: Genes and environment. Biological Psychiatry, 47, 210– 220
(2001). Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid and fetal brain. Schizophrenia Research, 47, 27– 36
(2003). Identification of a high risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high density schizophrenia families. Molecular Psychiatry, 8, 499– 510
(2002). Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings and healthy unrelated volunteers. American Journal of Psychiatry, 159, 1514– 1520
(2004). Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Archives of General Psychiatry, 61, 544– 555
(1995). From neuropathology to neurodevelopment. The Lancet, 346, 552– 557
(2005). Early studies of schizophrenia genomics. Clinical Therapy, 27, 8– 15
(2006). Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorders. Archives of Genetics and Psychiatry, 63, 366– 373
(1998). A meta-analysis and transmission disequilibrium study of the association between the dopamine D3 receptor gene and schizophrenia. Molecular Psychiatry, 3, 24– 28
(2000). Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia, 43, 373– 376
(